I hope you get this email before tonight.
| |
Hi Reader, I hope you get this email before tonight. One of Dave Lashmet's biotech recommendations just rose 51% in one morning, after completing Phase III trials for a new drug. Altogether, Dave's readers are now seeing a 100% gain. But frankly… we're not surprised. You could have doubled your money 9 different times over the past few years alone by following Dave's recommendations. That's why until midnight tonight, we're sharing details on Dave's newest pick… which he predicts could take off by 200% beginning soon. Just remember: We're not sharing this opportunity after today, November 19. After midnight tonight – we're pulling this offline. So if you're interested, I urge you to click here today for the full details. Regards, Justin Brill
Editor, The Stansberry Digest P.S. Until midnight tonight, you can also claim a free ebook outlining the broad scope of Dave's new investment opportunity. Learn how to get it right here. |
|
| |
All contents of this e-mail are copyright 2017 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.
DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.
You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to info@stansberrycustomerservice.com.
To unsubscribe from this mailing, click here: Unsubscribe
|
|
|
